JLE

Hépato-Gastro & Oncologie Digestive

MENU

Prevention of chemotherapy-induced neutropenia in digestive oncology Volume 26, supplement 1, Octobre 2019

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
1 CHRU de Tours, Hôpital Trousseau, Service d’hépato-gastroentérologie et de cancérologie digestive, 37044 Tours
2 Université François Rabelais, EA 7501 (GICC), 37032 Tours
* Correspondance

The risk of severe chemotherapy-induced neutropenia varies according to the chemotherapy regimen and clinico-biological factors. For instance, concerning the chemotherapy-based treatment of colorectal cancer, the risks of severe neutropenia that is grade 3 to 4 (<1.000 neutrophils/mm3) and febrile neutropenia range from 2% to 50 % and <1% to 10 %, respectively. For the majority of chemotherapy regimens prescribed in gastrointestinal oncology, the prevention and management of severe chemotherapy-induced neutropenia is mainly based on delaying cycles generally associated with decreasing drug dosage to the detriment of the regimen's intensity-dose ratio. For regimens associated with a higher risk of severe neutropenia such as DCF, VP16-platinum and FOLFIRINOX regimens, the prescription of G-CSF in primary or secondary prophylaxis should be discussed or recommended systematically. The search for a DPD deficiency before the prescription of 5-FU helps to prevent the risk of severe haematological toxicity related to 5-FU. The management of the risk of neutropenia attributable to the prescription of chemotherapy requires a good knowledge of the tolerance profiles of the prescribed chemotherapies and risk factors related to the patient.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License